Stock PRGO PERRIGO COMPANY PLC
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Perrigo Company plc TEL AVIV STOCK EXCHANGE

Equities

PRGO

IE00BGH1M568

Delayed TEL AVIV STOCK EXCHANGE
Other stock markets
 		5-day change 1st Jan Change
- ILa -.--% Intraday chart for Perrigo Company plc -2.55% -3.73%
28/05 Perrigo Company plc Announces Executive Changes CI
07/05 Perrigo's Q1 Adjusted Earnings, Net Sales Drop MT

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • The company's share price in relation to its net book value makes it look relatively cheap.
  • The company has a low valuation given the cash flows generated by its activity.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • Low profitability weakens the company.
  • One of the major weak points of the company is its financial situation.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
PERRIGO COMPANY PLC Stock Perrigo Company plc
-3.73% 376.79Cr -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+42.83% 75TCr
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+34.11% 60TCr
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.70% 36TCr
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.06% 33TCr
B-
ABBVIE INC. Stock AbbVie Inc.
+4.63% 28TCr
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+17.02% 24TCr
B+
NOVARTIS AG Stock Novartis AG
+9.26% 21TCr
B-
ROCHE HOLDING AG Stock Roche Holding AG
-4.21% 21TCr
A+
PFIZER, INC. Stock Pfizer, Inc.
+2.43% 17TCr
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. PRGO Stock
  4. PRGO Stock
  5. Ratings Perrigo Company plc